Three months of the chemotherapy combination of adriamycin (A) and cyclophosphamide (C) can replace six months of cyclophosphamide, methotrexate (M) and flurouracil (F) for women with early stage breast cancer without node involvement. Among more than 2,000 women enrolled in a National Surgical Adjuvant Breast and Bowel Project study, five-year disease-free survival for either treatment was about 82% and overall survival was about 89%, reports Bernard Fisher, of the NSABP at the recent ASCO meeting.
Go to Previous Page
Go to Next Page